MK 2206

Drug Profile

MK 2206

Alternative Names: BIND 2206; MK 2206 Accurin™; MK-2206; MK2206 tablets

Latest Information Update: 25 Jan 2017

Price : $50

At a glance

  • Originator Merck & Co; University of California at San Francisco
  • Developer AstraZeneca; Memorial Sloan-Kettering Cancer Center; Merck & Co; National Cancer Institute (USA); University of Texas M. D. Anderson Cancer Center
  • Class 3-ring heterocyclic compounds; Amines; Antineoplastics; Cyclobutanes
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Colorectal cancer; Haematological malignancies; Non-small cell lung cancer; Solid tumours
  • No development reported Neuroendocrine tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in United Kingdom (PO, Tablet)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO, Tablet)
  • 02 May 2016 BIND Therapeutics files for Chapter 11 bankruptcy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top